Hojjat-Farsangi M - Search Results

1

The imbalance of Th17/Treg axis involved in the pathogenesis of preeclampsia.

Eghbal-Fard S, Yousefi M, Heydarlou H, Ahmadi M, Taghavi S, Movasaghpour A, Jadidi-Niaragh F, Yousefi B, Dolati S, Hojjat-Farsangi M, Rikhtegar R, Nouri M, Aghebati-Maleki L. Eghbal-Fard S, et al. J Cell Physiol. 2019 Apr;234(4):5106-5116. doi: 10.1002/jcp.27315. Epub 2018 Oct 2. J Cell Physiol. 2019. PMID: 30277561

2

Increased frequency of CD8+ and CD4+ regulatory T cells in chronic lymphocytic leukemia: association with disease progression.

Jadidi-Niaragh F, Yousefi M, Memarian A, Hojjat-Farsangi M, Khoshnoodi J, Razavi SM, Jeddi-Tehrani M, Shokri F. Jadidi-Niaragh F, et al. Cancer Invest. 2013 Feb;31(2):121-31. doi: 10.3109/07357907.2012.756110. Epub 2013 Jan 3. Cancer Invest. 2013. PMID: 23286587

3

Differential regulation of B-cell proliferation by IL21 in different subsets of chronic lymphocytic leukemia.

Ghalamfarsa G, Jadidi-Niaragh F, Hojjat-Farsangi M, Asgarian-Omran H, Yousefi M, Tahmasebi F, Khoshnoodi J, Razavi SM, Saboor-Yaraghi AA, Rabbani H, Jeddi-Tehrani M, Shokri F. Ghalamfarsa G, et al. Cytokine. 2013 Jun;62(3):439-45. doi: 10.1016/j.cyto.2013.03.023. Epub 2013 Apr 9. Cytokine. 2013. PMID: 23579027

4

The skewed balance between Tregs and Th17 in chronic lymphocytic leukemia.

Yousefi M, Movassaghpour AA, Shamsasenjan K, Ghalamfarsa G, Sadreddini S, Jadidi-Niaragh F, Hojjat-Farsangi M. Yousefi M, et al. Future Oncol. 2015;11(10):1567-82. doi: 10.2217/fon.14.298. Future Oncol. 2015. PMID: 25963433 Review.

5

Folate-conjugated nanoparticles as a potent therapeutic approach in targeted cancer therapy.

Bahrami B, Mohammadnia-Afrouzi M, Bakhshaei P, Yazdani Y, Ghalamfarsa G, Yousefi M, Sadreddini S, Jadidi-Niaragh F, Hojjat-Farsangi M. Bahrami B, et al. Tumour Biol. 2015 Aug;36(8):5727-42. doi: 10.1007/s13277-015-3706-6. Epub 2015 Jul 5. Tumour Biol. 2015. PMID: 26142733 Free article. Review.

6

Ibrutinib-A double-edge sword in cancer and autoimmune disorders.

Kokhaei P, Jadidi-Niaragh F, Sotoodeh Jahromi A, Osterborg A, Mellstedt H, Hojjat-Farsangi M. Kokhaei P, et al. J Drug Target. 2016;24(5):373-85. doi: 10.3109/1061186X.2015.1086357. Epub 2015 Sep 11. J Drug Target. 2016. PMID: 26362595 Review.

7

Mechanisms of tumor cell resistance to the current targeted-therapy agents.

Khamisipour G, Jadidi-Niaragh F, Jahromi AS, Zandi K, Hojjat-Farsangi M. Khamisipour G, et al. Tumour Biol. 2016 Aug;37(8):10021-39. doi: 10.1007/s13277-016-5059-1. Epub 2016 May 7. Tumour Biol. 2016. PMID: 27155851 Review.

8

Application of nanomedicine for crossing the blood-brain barrier: Theranostic opportunities in multiple sclerosis.

Ghalamfarsa G, Hojjat-Farsangi M, Mohammadnia-Afrouzi M, Anvari E, Farhadi S, Yousefi M, Jadidi-Niaragh F. Ghalamfarsa G, et al. J Immunotoxicol. 2016 Sep;13(5):603-19. doi: 10.3109/1547691X.2016.1159264. Epub 2016 Jul 14. J Immunotoxicol. 2016. PMID: 27416019 Free article. Review.

9

Adenosine and adenosine receptors in the immunopathogenesis and treatment of cancer.

Kazemi MH, Raoofi Mohseni S, Hojjat-Farsangi M, Anvari E, Ghalamfarsa G, Mohammadi H, Jadidi-Niaragh F. Kazemi MH, et al. J Cell Physiol. 2018 Mar;233(3):2032-2057. doi: 10.1002/jcp.25873. Epub 2017 May 3. J Cell Physiol. 2018. PMID: 28233320 Review.

10

Nanoparticles and targeted drug delivery in cancer therapy.

Bahrami B, Hojjat-Farsangi M, Mohammadi H, Anvari E, Ghalamfarsa G, Yousefi M, Jadidi-Niaragh F. Bahrami B, et al. Immunol Lett. 2017 Oct;190:64-83. doi: 10.1016/j.imlet.2017.07.015. Epub 2017 Jul 29. Immunol Lett. 2017. PMID: 28760499 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

120 results

Search Page

Filters